Skip to main content
SpringerLink
Log in

X-Linked IAP

  • Reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 1862 Accesses

Abstract

X-linked inhibitor of apoptosis protein (XIAP) is a member of the family of inhibitor of apoptosis proteins and part of the programmed cell death (apoptosis) pathway. Also known as BIRC4 (baculovirus IAP repeat-containing 4), XIAP resides in the cytoplasm. It acts as an inhibitor of caspases by directly binding to and inhibiting caspases 3, 7, and 9 and thus may inhibit both the intrinsic and extrinsic apoptosis pathways. Protein and RNA levels of XIAP can be measured but there are currently no FDA-approved tests for the measurement of XIAP in either tumor tissue or blood. XIAP is overexpressed in numerous malignancies. XIAP is currently being investigated as a predictive and prognostic tool in cancer and as a marker of resistance to cancer therapies. Restoration of apoptosis is an important priority for cancer drug development, thus targeting of XIAP is of critical significance. Second mitochondrial-derived activator of caspases (SMAC)-mimetics such as LCL-161 and antisense oligonucleotides such as AEG35156 inhibit XIAP and are being investigated in therapeutic clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Dorsey FC, Steeves MA, Cleveland JL. Apoptosis, autophagy, and necrosis. In: Mendesohn J, Howley PM, Israel MA, Gray JW, Thompson CB, editors. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier; 2008. p. 207–10.

    Google Scholar 

  • Emanuel PO, Phelps RG, Mudgil A, et al. Immunohistochemical detection of XIAP in melanoma. J Cutan Pathol. 2008;35(3):292–7.

    Article  PubMed  Google Scholar 

  • Green DR. Means to an end: apoptosis and other cell death mechanisms. New York: Cold Spring Harbor Laboratory Press; 2011. p. 5–28.

    Google Scholar 

  • Kang HG, Lee SJ, Chae MH, Lee WK, Cha SK, Kim CH, Kam S, Park RW, Kim IS, Kim DS, Kim YC, Jung TH, Park JY. Identification of polymorphisms in the XIAP gene and analysis of association with lung cancer risk in a Korean population. Cancer Genet Cytogenet. 2008;180(1):6–13.

    Article  CAS  PubMed  Google Scholar 

  • Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res. 2010;16(18):4496–502.

    Article  CAS  PubMed  Google Scholar 

  • LaCasse EC. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett. 2013; 332(2):215–24. doi: 10.1016/j.canlet.2012.06.015. Epub 2012 Jul 7.

    Google Scholar 

  • Li J, Li ZN, Bao QL, Ge LP, Li XQ, Chen P. Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion. Tumour Biol. 2012;33(5):1803–10.

    Article  PubMed  Google Scholar 

  • Lodish H, Berk A, Kaiser CA, Krieger M, Bretscher A, Ploegh H, Amon A, Scott MP. Chapter 21: Molecular cell biology. 7th edn. In: Stem cells, asymmetry, and cell death. p. 1006–16. W. H Freeman and Company, New York/Houndsmills, Basingstoke.

    Google Scholar 

  • Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol. 2007;30(4):919–25.

    CAS  PubMed  Google Scholar 

  • Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10(11):3737–44.

    Article  CAS  PubMed  Google Scholar 

  • Wiki.medipedia.com/x_linkied_Inhibitor_of_apoptosis_(XIAP). Accessed 3 Mar 2013.

    Google Scholar 

  • Wu M, Kafanas A, Gan L, Kohtz DS, Zhang L, Genden E, et al. Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma. Diagn Cytopathol. 2008;36(11):797–800.

    Article  CAS  PubMed  Google Scholar 

  • www.clinicaltrials.gov. Accessed 4 Mar 2013.

  • Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol. 2009;100:708–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, A445 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH, 43210, USA

    Anne Noonan

Authors
  1. Anne Noonan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Noonan .

Editor information

Editors and Affiliations

  1. Division of Hematology & Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media, New York (outside the USA)

About this entry

Cite this entry

Noonan, A. (2017). X-Linked IAP. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_68

Download citation

Publish with us

Policies and ethics

Search

Navigation